Pilocarpine-induced epilepsy in mice alters seizure thresholds and the efficacy of antiepileptic drugs in the 6-Hertz psychomotor seizure model

Epilepsy Research

Volumn 107, Issue 3, 2013, Pages 205-216

  Bankstahl, Marion ^a,b   Bankstahl, Jens P ^a,b   Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Levetiracetam; Pharmacoresistance; Phenobarbital; Phenytoin; Retigabine; SV2A

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; PHENOBARBITAL; PHENYTOIN; PILOCARPINE; RETIGABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SENSITIVITY; ELECTRIC SHOCK; FEMALE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOMOTOR SEIZURE; SEIZURE; SEIZURE THRESHOLD; TEMPORAL LOBE EPILEPSY;

AED; ANTIEPILEPTIC DRUG; CC; CONVULSANT CURRENT; ED; EFFECTIVE DOSE; HERTZ; HZ; LEVETIRACETAM; MAXIMAL ELECTROSHOCK SEIZURE; MES; PENTYLENETETRAZOLE; PHARMACORESISTANCE; PHENOBARBITAL; PHENYTOIN; PTZ; RETIGABINE; SE; STATUS EPILEPTICUS; SV2A; SYNAPTIC VESICLE PROTEIN 2A; TEMPORAL LOBE EPILEPSY; TLE;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; FEMALE; MALE; MICE; PILOCARPINE; SEIZURES; TREATMENT OUTCOME;

EID: 84888436989     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.09.014     Document Type: Article

References (35)

1. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001, 47:217-228.
2. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009, 83:1-43.
3. Blanco M.M., Dos S.J., Perez-Mendes P., Kohek S.R., Cavarsan C.F., Hummel M., Albuquerque C., Mello L.E. Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models. Epilepsia 2009, 50:824-831.
4. Brown W.C., Schiffman D.O., Swinyard E.A., Goodman L.S. Comparative assay of antiepileptic drugs by "pychomotor" seizure test and minimal electroshock threshold test. J. Pharmacol. Exp. Ther. 1953, 107:273-283.
5. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. U.S.A. 1999, 96:15268-15273.
6. Curia G., Longo D., Biagini G., Jones R.S., Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods 2008, 172:143-157.
7. Finney D.J. Probit Analysis 1971, Cambridge University Press, London. 3rd ed.
8. Galanopoulou A.S., Buckmaster P.S., Staley K.J., Moshe S.L., Perucca E., Engel J., Löscher W., Noebels J.L., Pitkanen A., Stables J., White H.S., O'Brien T.J. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012, 53:571-582. Simonato for The American Epilepsy Society Basic Science Committee and The International League Against Epilepsy Working Group on Recommendations for Preclinical Epilepsy Drug Discovery.
9. Gladding G.D., Kupferberg H.J., Swinyard E.A. Antiepileptic drug development program. Antiepileptic Drugs 1985, 341-350. Springer, Berlin. H.-H. Frey, D. Janz (Eds.).
10. Green A.R., Murray T.K. A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms. J. Pharm. Pharmacol. 1989, 41:879-880.
11. Gröticke I., Hoffmann K., Löscher W. Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp. Neurol. 2007, 207:329-349.
12. Haller J., Alicki M. Current animal models of anxiety, anxiety disorders, and anxiolytic drugs. Curr. Opin. Psychiatry 2012, 25:59-64.
13. Hoffmann K., Czapp M., Löscher W. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?. Epilepsy Res. 2008, 81:107-113.
14. Kaminski R.M., Gillard M., Leclercq K., Hanon E., Lorent G., Dassesse D., Matagne A., Klitgaard H. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009, 50:1729-1740.
15. Kaminski R.M., Gillard M., Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. Jasper's Basic Mechanisms of the Epilepsies 2012, 974-983. Oxford, New York. 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
16. Kwan P., Schachter S.C., Brodie M.J. Drug-resistant epilepsy. N. Engl. J. Med. 2011, 365:919-926.
17. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-response experiments. J. Pharmacol. Exp. Ther. 1949, 96:99-113.
18. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8:79-94.
19. Löscher W., Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 1993, 232:147-158.
20. Löscher W., Ebert U. Basic mechanisms of seizure propagation: Targets for rational drug design and rational polypharmacy. Epilepsy Res Suppl. 1996, 11:17-44.
21. Löscher W., Dekundy A., Nagel J., Danysz W., Parsons C.G., Potschka H. mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy. Neuropharmacology 2006, 50:1006-1015.
22. Löscher W. Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur. J. Pharmacol. 2009, 610:1-11.
23. Löscher W., Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011, 52:657-678.
24. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
25. Matveeva E.A., Vanaman T.C., Whiteheart S.W., Slevin J.T. Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsia 2008, 49:1749-1758.
26. Nowack A., Malarkey E.B., Yao J., Bleckert A., Hill J., Bajjalieh S.M. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS One 2011, 6:e29560.
27. Ohno Y., Ishihara S., Terada R., Kikuta M., Sofue N., Kawai Y., Serikawa T., Sasa M. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling. Biochem. Biophys. Res. Commun. 2009, 390:415-420.
28. Rattka M., Brandt C., Bankstahl M., Bröer S., Löscher W. Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats. Neuropharmacology 2011, 60:505-512.
29. Rattka M., Brandt C., Löscher W. Do proconvulsants modify or halt epileptogenesis? Pentylenetetrazole is ineffective in two rat models of temporal lobe epilepsy. Eur. J. Neurosci. 2012, 36:2505-2520.
30. Smith M., Wilcox K.S., White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
31. Toman J.E.P. Experimental psychomotor seizures. Electroencephalogr. Clin. Neurophysiol. 1951, 3:253.
32. van Vliet E.A., Aronica E., Redeker S., Boer K., Gorter J.A. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 2009, 50:422-433.
33. White H.S., Smith-Yockman M., Srivastava A., Wilcox K.S. Therapeutic assays for the identification and characterization of antiepileptic and antiepileptogenic drugs. Models of Seizures and Epilepsy 2006, 539-549. Elsevier, Amsterdam. A. Pitkänen, P.A. Schwartzkroin, S.L. Moshé (Eds.).
34. Winden K.D., Karsten S.L., Bragin A., Kudo L.C., Gehman L., Ruidera J., Geschwind D.H., Engel J. A systems level, functional genomics analysis of chronic epilepsy. PLoS One 2011, 6:e20763.
35. Wlaz P., Potschka H., Löscher W. Frontal versus transcorneal stimulation to induce maximal electroshock seizures or kindling in mice and rats. Epilepsy Res. 1998, 30:219-229.